Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2019,（2）
• 页码范围: 107-108
• 页数: 2页
• 语种: 英文

摘要

PROSPER is an international Phase Ⅲ trial demonstrating the beneficial role of enzalutamide,an androgen receptor antagonist,in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer.The trial showed that the median metastasis-free survival was 21.9 months longer for those treated with enzalutamide (36.6 months)compared to those treated with placebo (14.7 months).Enzalutamide also showed prolonged time to PSA progression,PSA response,and time to initiating additional antineoplastic therapy although overall survival is not yet reached.Enzalutamide is the second antiandrogen (next to apalutamide) that has gained the United States Food and Drug Administration (US FDA) label indication for use in the setting of nonmetastatic castration-resistant prostate cancer.